首页> 美国卫生研究院文献>British Journal of Cancer >Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer

【2h】

Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer

机译：乳腺癌干细胞标志物的表达可预测HER2阳性乳腺癌的预后和对曲妥珠单抗的反应

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Breast cancer stem cells (BCSCs) have been suggested to have clinical implications for cancer therapeutics because of their proposed role in chemoresistance. The aim of this study was to investigate the impact of BCSC marker expression on clinical outcome and trastuzumab response in human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

机译：背景：乳腺癌干细胞（BCSC）已被建议对癌症治疗具有临床意义，因为它们在化学抗性中具有拟议的作用。这项研究的目的是调查BCSC标志物表达对人表皮生长因子受体2（HER2）阳性乳腺癌的临床结局和曲妥珠单抗反应的影响。

著录项

期刊名称 British Journal of Cancer
作者
An Na Seo; Hee Jin Lee; Eun Joo Kim; Min Hye Jang; Yu Jung Kim; Jee Hyun Kim; Sung-Won Kim; Han Suk Ryu; In Ae Park; Seock-Ah Im; Gyungyub Gong; Kyung Hae Jung; Hee Jeong Kim; So Yeon Park;
展开▼
作者单位

展开▼
年(卷),期 2016(114),10
年度 2016
页码 1109–1116
总页数 8
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
breast cancer HER2 breast cancer stem cell prognosis trastuzumab;

机译：乳腺癌;HER2;乳腺癌干细胞;预后;曲妥珠单抗;

相似文献

外文文献
中文文献
专利

1. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer [J] . Koo Dong-Hoe, Lee Hee Jin, Ahn Jin-Hee, Tumour biology : . 2015,第8期

机译：Tau和PTEN状态是HER2阳性乳腺癌患者对曲妥珠单抗和紫杉醇反应的预测指标
2. HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients [J] . Tao Qin, Zhongyu Yuan, Roujun Peng, OncoTargets and therapy . 2013,第4期

机译：接受曲妥珠单抗治疗的HER2阳性乳腺癌患者的预后与HER2阴性乳腺癌患者的预后相当
3. Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer. [J] . M Tanioka, K Sakai, T Sudo, Breast cancer research and treatment. . 2014,第3期

机译：转录CCND1表达可预测曲妥珠单抗对HER2阳性/ ER阳性乳腺癌新辅助化疗反应不良。
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. Gut Microbiota and Trastuzumab Response in HER2-Positive Breast Cancer [D] . Di Modica, Martina. 2020

机译：肠道微生物群和胸瘤反应在Her2阳性乳腺癌中
6. Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort [O] . Anne-Sophie Hamy, Lisa Belin, Hélène Bonsang-Kitzis, 2018

机译：曲妥珠单抗时代前后HER2阳性乳腺癌新辅助化疗后的病理学完全缓解和预后：来自真实队列的结果
7. HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients [O] . Tao Qin 2013

机译：HER2阳性乳腺癌患者接受曲妥珠单抗治疗可与HER2阴性乳腺癌患者的预后相当

Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer

摘要

著录项

相似文献

相关主题

期刊订阅